Copyright Reports & Markets. All rights reserved.

Global Beta-lactam and Beta-lactamase Inhibitors Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Penicillin
      • 1.4.3 Cephalosporin
      • 1.4.4 Carbapenem
      • 1.4.5 Monobactam
      • 1.4.6 Combination
    • 1.5 Market by Application
      • 1.5.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Application (2019-2025)
      • 1.5.2 Oral
      • 1.5.3 Intravenous
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Beta-lactam and Beta-lactamase Inhibitors Market Size
    • 2.2 Beta-lactam and Beta-lactamase Inhibitors Growth Trends by Regions
      • 2.2.1 Beta-lactam and Beta-lactamase Inhibitors Market Size by Regions (2019-2025)
      • 2.2.2 Beta-lactam and Beta-lactamase Inhibitors Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Beta-lactam and Beta-lactamase Inhibitors Market Size by by Players
      • 3.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by by Players (2014-2019)
      • 3.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.2 Beta-lactam and Beta-lactamase Inhibitors Key Players Head office and Area Served
    • 3.3 Key Players Beta-lactam and Beta-lactamase Inhibitors Product/Solution/Service
    • 3.4 Date of Enter into Beta-lactam and Beta-lactamase Inhibitors Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Type (2014-2019)
    • 4.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
    • 5.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in North America
    • 5.3 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
    • 5.4 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

    6 Europe

    • 6.1 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
    • 6.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in Europe
    • 6.3 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
    • 6.4 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

    7 China

    • 7.1 China Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
    • 7.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in China
    • 7.3 China Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
    • 7.4 China Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

    8 Japan

    • 8.1 Japan Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
    • 8.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in Japan
    • 8.3 Japan Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
    • 8.4 Japan Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
    • 9.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in Southeast Asia
    • 9.3 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
    • 9.4 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

    10 India

    • 10.1 India Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
    • 10.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in India
    • 10.3 India Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
    • 10.4 India Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Size (2014-2019)
    • 11.2 Beta-lactam and Beta-lactamase Inhibitors Key Players in Central & South America
    • 11.3 Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
    • 11.4 Central & South America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

    12 International Players Profiles

    • 12.1 Abbott Laboratories
      • 12.1.1 Abbott Laboratories Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
      • 12.1.4 Abbott Laboratories Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019))
      • 12.1.5 Abbott Laboratories Recent Development
    • 12.2 Allergan Plc.
      • 12.2.1 Allergan Plc. Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
      • 12.2.4 Allergan Plc. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
      • 12.2.5 Allergan Plc. Recent Development
    • 12.3 F. Hoffmann-La Roche Ltd.
      • 12.3.1 F. Hoffmann-La Roche Ltd. Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
      • 12.3.4 F. Hoffmann-La Roche Ltd. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
      • 12.3.5 F. Hoffmann-La Roche Ltd. Recent Development
    • 12.4 GlaxoSmithKline plc
      • 12.4.1 GlaxoSmithKline plc Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
      • 12.4.4 GlaxoSmithKline plc Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
      • 12.4.5 GlaxoSmithKline plc Recent Development
    • 12.5 Merck & Co. Inc.
      • 12.5.1 Merck & Co. Inc. Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
      • 12.5.4 Merck & Co. Inc. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
      • 12.5.5 Merck & Co. Inc. Recent Development
    • 12.6 Mylan N.V.
      • 12.6.1 Mylan N.V. Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
      • 12.6.4 Mylan N.V. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
      • 12.6.5 Mylan N.V. Recent Development
    • 12.7 Novartis International AG (Sandoz)
      • 12.7.1 Novartis International AG (Sandoz) Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
      • 12.7.4 Novartis International AG (Sandoz) Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
      • 12.7.5 Novartis International AG (Sandoz) Recent Development
    • 12.8 Pfizer Inc.
      • 12.8.1 Pfizer Inc. Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
      • 12.8.4 Pfizer Inc. Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
      • 12.8.5 Pfizer Inc. Recent Development
    • 12.9 Sanofi
      • 12.9.1 Sanofi Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
      • 12.9.4 Sanofi Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
      • 12.9.5 Sanofi Recent Development
    • 12.10 Teva Pharmaceutical Industries Ltd
      • 12.10.1 Teva Pharmaceutical Industries Ltd Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Beta-lactam and Beta-lactamase Inhibitors Introduction
      • 12.10.4 Teva Pharmaceutical Industries Ltd Revenue in Beta-lactam and Beta-lactamase Inhibitors Business (2014-2019)
      • 12.10.5 Teva Pharmaceutical Industries Ltd Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Beta-lactam antibiotics are a class of antibiotics consisting of all antibiotic agents that contain a beta-lactam ring in their molecular structures. This includes penicillin derivatives, cephalosporins, monobactams, and carbapenems.
      These are the antimicrobial substances or compounds that fight against bacterial infections and sometimes with protozoan infections. In addition, these medications either kill the bacteria directly or stop the bacteria from growing. However, these drugs are easily available at over-the-counter (OTC) and one can buy these without a prescription in most of the countries, which leads to overuse or misuse. Thereby, bacterial resistance is developing the beta-lactam antibiotics.
      In 2018, the global Beta-lactam and Beta-lactamase Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Beta-lactam and Beta-lactamase Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Beta-lactam and Beta-lactamase Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Abbott Laboratories
      Allergan Plc.
      F. Hoffmann-La Roche Ltd.
      GlaxoSmithKline plc
      Merck & Co. Inc.
      Mylan N.V.
      Novartis International AG (Sandoz)
      Pfizer Inc.
      Sanofi
      Teva Pharmaceutical Industries Ltd

      Market segment by Type, the product can be split into
      Penicillin
      Cephalosporin
      Carbapenem
      Monobactam
      Combination

      Market segment by Application, split into
      Oral
      Intravenous
      Others

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Beta-lactam and Beta-lactamase Inhibitors status, future forecast, growth opportunity, key market and key players.
      To present the Beta-lactam and Beta-lactamase Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Beta-lactam and Beta-lactamase Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now